These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 21636156)

  • 1. DPP-IV inhibitor may affect spermatogenesis.
    Hibi H; Ohori T; Yamada Y
    Diabetes Res Clin Pract; 2011 Aug; 93(2):e74-e75. PubMed ID: 21636156
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DPP-IV inhibitor-associated arthralgias.
    Chaicha-Brom T; Yasmeen T
    Endocr Pract; 2013; 19(2):377. PubMed ID: 23598537
    [No Abstract]   [Full Text] [Related]  

  • 3. Angio-oedema induced by dual dipeptidyl peptidase inhibitor and angiotensin II receptor blocker: a first case report.
    Skalli S; Wion-Barbot N; Baudrant M; Lablanche S; Benhamou PY; Halimi S
    Diabet Med; 2010 Apr; 27(4):486-7. PubMed ID: 20536525
    [No Abstract]   [Full Text] [Related]  

  • 4. [Dipeptidylpeptidase-4 (DPP-4) inhibitor sitagliptin. Cardiovascular safety in type 2 diabetics].
    MMW Fortschr Med; 2014 Jul; 156(13):74-5. PubMed ID: 25318234
    [No Abstract]   [Full Text] [Related]  

  • 5. Looking to the future: focus on DPP-4 inhibitors for the treatment of type 2 diabetes and emerging therapies.
    Neumiller JJ; Odegard PS; White JR; Setter SM; Campbell RK
    Diabetes Educ; 2008; 34(2):183-200. PubMed ID: 18375772
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin in older adults with type 2 diabetes mellitus.
    Stafford S; Elahi D; Meneilly GS
    J Am Geriatr Soc; 2011 Jun; 59(6):1148-9. PubMed ID: 21668924
    [No Abstract]   [Full Text] [Related]  

  • 7. [A new therapeutic possibility for type 2 diabetes: DPP-4 inhibitors (sitagliptin)].
    Abel T; Fehér J
    Orv Hetil; 2010 Jun; 151(25):1012-6. PubMed ID: 20519186
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sitagliptin phosphate: a DPP-4 inhibitor for the treatment of type 2 diabetes mellitus.
    Erol A
    Clin Ther; 2008 Apr; 30(4):785-6; author reply 786. PubMed ID: 18498926
    [No Abstract]   [Full Text] [Related]  

  • 9. [Sitagliptin].
    Taéron C
    Rev Infirm; 2008 Oct; (144):46-8. PubMed ID: 19009789
    [No Abstract]   [Full Text] [Related]  

  • 10. Sitagliptin (DPP-4 inhibitor)-induced rheumatoid arthritis in type 2 diabetes mellitus: a case report.
    Yokota K; Igaki N
    Intern Med; 2012; 51(15):2041-4. PubMed ID: 22864134
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sitagliptin 100 mg daily effect on DPP-4 inhibition and compound-specific glycemic improvement.
    Alba M; Sheng D; Guan Y; Williams-Herman D; Larson P; Sachs JR; Thornberry N; Herman G; Kaufman KD; Goldstein BJ
    Curr Med Res Opin; 2009 Oct; 25(10):2507-14. PubMed ID: 19691426
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sitagliptin: a review.
    Subbarayan S; Kipnes M
    Expert Opin Pharmacother; 2011 Jul; 12(10):1613-22. PubMed ID: 21651449
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug reaction with eosinophilia and systemic symptoms (DRESS) in a patient taking sitagliptin.
    Sin C; Mahé E; Sigal ML
    Diabetes Metab; 2012 Dec; 38(6):571-3. PubMed ID: 23183246
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elevated hepatic enzymes potentially associated with sitagliptin.
    Gross BN; Cross LB; Foard J; Wood Y
    Ann Pharmacother; 2010 Feb; 44(2):394-5. PubMed ID: 20103614
    [No Abstract]   [Full Text] [Related]  

  • 15. All-cause mortality and cardiovascular effects associated with the DPP-IV inhibitor sitagliptin compared with metformin, a retrospective cohort study on the Danish population.
    Scheller NM; Mogensen UM; Andersson C; Vaag A; Torp-Pedersen C
    Diabetes Obes Metab; 2014 Mar; 16(3):231-6. PubMed ID: 24020750
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sitagliptin combined with sulphonylureas: new indication. Other treatments are preferable.
    Prescrire Int; 2009 Feb; 18(99):14-5. PubMed ID: 19391232
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sitagliptin-associated drug allergy: review of spontaneous adverse event reports.
    Desai S; Brinker A; Swann J; Iyasu S
    Arch Intern Med; 2010 Jul; 170(13):1169-71. PubMed ID: 20625027
    [No Abstract]   [Full Text] [Related]  

  • 18. Sitagliptin, a dipeptidyl peptidase-IV inhibitor, improves psoriasis.
    Nishioka T; Shinohara M; Tanimoto N; Kumagai C; Hashimoto K
    Dermatology; 2012; 224(1):20-1. PubMed ID: 22056790
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sitagliptin--another option for managing type 2 diabetes in dialysis patients?
    St Peter WL; Weinhandl ED; Flessner MF
    Am J Kidney Dis; 2013 Apr; 61(4):532-5. PubMed ID: 23497767
    [No Abstract]   [Full Text] [Related]  

  • 20. Discovery of JANUVIA (Sitagliptin), a selective dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
    Thornberry NA; Weber AE
    Curr Top Med Chem; 2007; 7(6):557-68. PubMed ID: 17352677
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.